Phase 2 N=39 Treatment

Candin Safety & Efficacy Study for the Treatment of Warts

Warts · Human Papilloma Virus

Bottom Line

View on ClinicalTrials.gov: NCT01757392 ↗

Enrolled (actual)

Serious AEs

2.9%

Results posted

Jan 2021

Primary outcome: Primary: Number of Participants With Complete Resolution of Primary Injected Wart — 19 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Candida albicans Skin Test Antigen (Biological)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Nielsen BioSciences, Inc.
Primary completion: Dec 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Complete Resolution of Primary Injected Wart	19	—
SECONDARY Number of Participants With Complete Resolution of the Primary Injected Wart by Number of Injection Visits	5; 4; 3; 4; 1; 2	—

Summary

The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).

Eligibility Criteria

Inclusion Criteria

Must have at least 3 and not more than 10 common warts not located on the palms or digits
Positive DTH response to Candin® required

Exclusion Criteria

No previous medical treatment for warts other than OTC
No immunocompromising medical conditions or medicines allowed
No preexisting inflammatory conditions at treatment site allowed

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01757392). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.